National Cancer Institute, Bethesda, MD 20892, USA.
Leuk Lymphoma. 2010 Aug;51 Suppl 1:28-33. doi: 10.3109/10428194.2010.500051.
Positron emission tomography (PET) is widely used for post-treatment response assessment in lymphoma. However, the role of PET in prognosis and early response assessment is still being defined. Studies have shown that PET can identify response early during chemotherapy and that interim PET can predict outcome in diffuse large B-cell lymphoma (DLBCL). Whether the results of early or post-treatment response assessment can be used to determine prognosis and/or guide therapeutic decisions, known as response-adapted therapy, is currently being investigated, with considerable promise in certain lymphomas such as Hodgkin lymphoma (HL) and DLBCL. The use of interim PET is currently limited by a lack of standardized imaging protocols and reporting criteria, and unproven reproducibility of interpretation. As a result, until further data are generated and a consensus reached, interim PET should be considered investigational and applied only within the confines of clinical studies. This review provides an overview of the use of PET for prognosis and response assessment, and in response-adapted therapy. Current limitations of the technique will be summarized, and innovative uses of PET in grading, staging, and surveying lymphomas will be briefly explored.
正电子发射断层扫描（PET）广泛用于淋巴瘤治疗后的反应评估。然而，PET 在预后和早期反应评估中的作用仍在确定中。研究表明，PET 可以在化疗期间早期识别反应，中期 PET 可以预测弥漫性大 B 细胞淋巴瘤（DLBCL）的结果。早期或治疗后反应评估的结果是否可用于确定预后和/或指导治疗决策，即所谓的反应适应性治疗，目前正在研究中，在霍奇金淋巴瘤（HL）和 DLBCL 等某些淋巴瘤中具有很大的前景。中期 PET 的使用目前受到缺乏标准化成像协议和报告标准以及解释的重现性未经证实的限制。因此，在进一步的数据生成和达成共识之前，中期 PET 应被视为研究性的，仅在临床研究的范围内使用。本综述介绍了 PET 在预后和反应评估以及反应适应性治疗中的应用。本文总结了该技术的当前局限性，并简要探讨了 PET 在分级、分期和淋巴瘤普查中的创新应用。
